Biomarkers in cancer immunotherapy.
暂无分享,去创建一个
Ton N Schumacher | Can Kesmir | T. Schumacher | Marit M. van Buuren | C. Keşmir | Marit M van Buuren
[1] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[2] Jimmy Lin,et al. Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.
[3] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[4] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[5] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.
[6] M. Stratton,et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Pia Kvistborg,et al. The cancer antigenome , 2012, The EMBO journal.
[8] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[9] Michael R Stratton,et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma , 2014, Nature Medicine.
[10] T. Schumacher,et al. High sensitivity of cancer exome-based CD8 T cell neo-antigen identification , 2014, Oncoimmunology.